NDLI: Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Please wait, while we are loading the content...

Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/ß-catenin/cyclin D1 signaling pathway in rats.

Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.

Tamoxifen downregulates ets oncogene family members ETV4 and ETV5 in benign breast tissue: implications for durable risk reduction.

Phenylbutyl isoselenocyanate modulates phase I and II enzymes and inhibits 4-(methylnitrosamino)-1-(3-pyridyl)- 1-butanone-induced DNA adducts in mice.

Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study.

Prospective investigation of poultry and fish intake in relation to cancer risk.

Mammography and ultrasound imaging of preinvasive and invasive canine spontaneous mammary cancer and their similarities to human breast cancer.

Lung cancer risk prediction to select smokers for screening CT--a model based on the Italian COSMOS trial.

Dietary folate deficiency blocks prostate cancer progression in the TRAMP model.

Methyl selenocysteine: single-dose pharmacokinetics in men.

Mitochondrial DNA copy number and pancreatic cancer in the alpha-tocopherol beta-carotene cancer prevention study.

Ethanol promotes chemically induced oral cancer in mice through activation of the 5-lipoxygenase pathway of arachidonic acid metabolism.

(3-Chloroacetyl)-indole, a novel allosteric AKT inhibitor, suppresses colon cancer growth in vitro and in vivo.

Inhibition by resistant starch of red meat-induced promutagenic adducts in mouse colon.

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk.

Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer.

Retraction. Psoralidin, an herbal molecule, inhibits phosphatidylinositol 3-kinase-mediated Akt signaling in androgen-independent prostate cancer cells.

Chronic nicotine consumption does not influence 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis.

Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer.

Long-term nicotine replacement therapy: cancer risk in context.

How do we safely get people to stop smoking?

Year: 2011 Volume: 4 Issue: 10

Year: 2011 Volume: 4 Issue: 9

Year: 2011 Volume: 4 Issue: 8

Year: 2011 Volume: 4 Issue: 7

Year: 2011 Volume: 4 Issue: 6

Year: 2011 Volume: 4 Issue: 5

Year: 2011 Volume: 4 Issue: 4

Year: 2011 Volume: 4 Issue: 3

Year: 2011 Volume: 4 Issue: 2

Year: 2011 Volume: 4 Issue: 1

Year: 2010 Volume: 3

Year: 2009 Volume: 2

Year: 2008 Volume: 1

Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Lee, Jung Eun Baba, Yoshifumi Ng, Kimmie Giovannucci, Edward Fuchs, Charles S. Ogino, Shuji Chan, Andrew T.
Spatial Coverage	Boston
Description	Author Affiliation: Lee JE ( Department of Food and Nutrition, Sookmyung Women's University, Seoul, Korea.)
Abstract	Use of statins is hypothesized to reduce colorectal cancer risk but the evidence remains inconsistent. This may be partly explained by differential associations according to tumor location or molecular subtypes of colorectal cancer. We examined the association between statin use and colorectal cancer risk according to tumor location, KRAS mutation status, microsatellite instability (MSI) status, PTGS2 (COX-2) expression, or CpG island methylator phenotype (CIMP) status in two large prospective cohort studies, the Nurses' Health Study and Health Professionals Follow-up Study. We applied Cox regression to a competing risks analysis. We identified 1,818 colorectal cancers during 1990 to 2006. Compared with nonusers, current statin use was not associated with colorectal cancer [relative risk (RR) = 0.99, 95% CI = 0.86-1.14] or colon cancer (RR = 1.10, 95% CI = 0.94-1.29) but was inversely associated with rectal cancer (RR = 0.59, 95% CI = 0.41-0.84, P(heterogeneity) < 0.001). When we examined the association within strata of KRAS mutation status, we found no association with KRAS-mutated cancers (RR = 1.20, 95% CI = 0.87-1.67) but did observe a possible inverse association among KRAS wild-type cancers (RR = 0.80, 95% CI = 0.60-1.06, P(heterogeneity) = 0.06). The association did not substantially differ by PTGS2 expression, MSI status, or CIMP status. Current statin use was not associated with risk of overall colorectal cancer. The possibility that statin use may be associated with lower risk of rectal cancer or KRAS wild-type colorectal cancer requires further confirmation.
File Format	HTM / HTML
ISSN	19406207
e-ISSN	19406215
DOI	10.1158/1940-6207.CAPR-11-0113
Journal	Cancer Prevention Research
Issue Number	11
Volume Number	4
Language	English
Publisher	American Association for Cancer Research
Publisher Date	2011-11-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Oncology Colorectal Neoplasms Etiology Cpg Islands Genetics Cyclooxygenase 2 Hydroxymethylglutaryl-coa Reductase Inhibitors Adverse Effects Microsatellite Instability Mutation Proto-oncogene Proteins Ras Proteins Boston Epidemiology Classification Drug Therapy Dna Methylation Administration & Dosage Phenotype Prognosis Prospective Studies Proto-oncogene Proteins P21(ras) Retrospective Studies Risk Factors Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women.

Left-Sided Early-Onset vs Late-Onset Colorectal Carcinoma: Histologic, Clinical, and Molecular Differences

CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors.

Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer

Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.

Similar Documents

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women.

Left-Sided Early-Onset vs Late-Onset Colorectal Carcinoma: Histologic, Clinical, and Molecular Differences

CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors.

Assessing tumor mutations to gain insight into base excision repair sequence polymorphisms and smoking in colon cancer

Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.

Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies.